A new year means a new Fierce Biotech Fundraising Tracker to record all the venture capital being funneled into the industry for 2024. We're bumping up our reporting criteria from last year's ...

President-elect Trump has nominated biotech investor Jim O’Neill for deputy secretary of the Health and Human Services department. The HHS deputy secretary oversees the day-to-day operations of ...

CRISPR Therapeutics partnered with big biotech player Vertex Pharmaceuticals on Casgevy, and the companies started rolling out the therapy this year. So far, 45 treatment centers have been ...

J.P. Morgan said its top biotech picks for 2025 were Vertex (NASDAQ:VRTX), Travere (NASDAQ:TVTX), SpringWorks (NASDAQ:SWTX), PTC Therapeutics (NASDAQ:PTCT), Wave Life Sciences (NASDAQ:WVE), Xenon ...

WASHINGTON — Legislation targeting Chinese biotechnology companies caused a ruckus early this year. None of that may matter if Congress doesn’t pass it in December. The BIOSECURE Act would ...

Roche has agreed to buy the biotech for $9 a share in cash. A further $4 a share is tied to the achievement of certain milestones. The total equity value of the deal is $1.5 billion. The outlay ...

Meet the beaten-down biotech that Wood loves and Wall Street says may soar more than 65% over the coming 12 months. First, though, let's delve a little farther into Cathie Wood's strategy.

Founded in 2020, the local biotech is working on gene therapies for neuromuscular diseases, which can interfere with a person’s muscles and nerves. These conditions are often inherited ...

Sloths weren't always slow-moving, furry tree-dwellers. Their prehistoric ancestors were huge—up to 4 tons (3.6 metric tons)—and when startled, they brandished immense claws. If all the world ...

Paradigm Biopharmaceuticals Ltd (ASX: PAR) shares started the week with an almighty bang. The ASX biotech stock ended the session almost 42% higher at 46 cents. At one stage, the biopharmaceutical ...

As we step into the final month of the year, let's take a look at the biotech companies whose drugs are under regulatory review in the U.S., with crucial decisions expected in December.